On Tuesday, December 16, the second Rudra kill party emerged in “Sanctuary,” the final raid of Season 1 in AION 2. It was a ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the ...

The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...

The FLAMINGO-01 DSMB met twice in 2025, most recently in December 2025, and recommended to continue the study as is without modification. The Steering Committee also met at SABCS 2025 and discussed ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest analysis on the stock here.

The General Services Administration has launched the second phase of the One Acquisition Solution for Integrated Services Plus, or OASIS+, contract program, adding five new service domains as part of ...

NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...

The biggest stories of the day delivered to your inbox.

Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...

The company targets revenue of >€215M with operational EBITDA margins expanding from 11% to 13-15%, representing 40-60% higher EBITDA by 2028. Priority areas for the coming years include portfolio mix ...

NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...

Broker Canaccord Genuity said Strategy’s (MSTR) transformation into a “full-cap-structure bitcoin acquisition engine” hit a new milestone with its first S&P credit rating, a B- with a stable outlook ...